Estipham has signed a supply contract for active pharmaceutical ingredients for oligonucleotide therapeutics. This contract is the largest single agreement to date and marks the third major order this year.
On September 18, Estipham announced that it has entered into a supply contract worth $66.1 million (approximately 913 billion won) with a global biotech company based in the United States.
The contract is effective from this year until November 2027. The customer has not been disclosed due to confidentiality agreements. The contract value represents about 27.5% of Estipham's total annual revenue of 331.7 billion won last year.
Estipham has been securing large orders this year, having previously signed contracts for oligonucleotide active pharmaceutical ingredients worth 82.5 billion won in January and 89.7 billion won in March.
To meet the growing demand in the oligonucleotide therapeutics market, Estipham has been expanding its production capacity. Last year, it completed the expansion of its second oligonucleotide production facility, enhancing its ability to produce active pharmaceutical ingredients.
In addition to oligonucleotide active pharmaceutical ingredients, Estipham operates a CDMO business that provides services necessary for drug development and production processes, including process analysis and regulatory changes. The company offers customized services from the early development stage through to process, analysis, and regulatory approval.
An Estipham representative stated, "We will continue to expand our collaborations with global big pharma and biotech companies."
On September 18, Estipham announced that it has entered into a supply contract worth $66.1 million (approximately 913 billion won) with a global biotech company based in the United States.
The contract is effective from this year until November 2027. The customer has not been disclosed due to confidentiality agreements. The contract value represents about 27.5% of Estipham's total annual revenue of 331.7 billion won last year.
Estipham has been securing large orders this year, having previously signed contracts for oligonucleotide active pharmaceutical ingredients worth 82.5 billion won in January and 89.7 billion won in March.
To meet the growing demand in the oligonucleotide therapeutics market, Estipham has been expanding its production capacity. Last year, it completed the expansion of its second oligonucleotide production facility, enhancing its ability to produce active pharmaceutical ingredients.
In addition to oligonucleotide active pharmaceutical ingredients, Estipham operates a CDMO business that provides services necessary for drug development and production processes, including process analysis and regulatory changes. The company offers customized services from the early development stage through to process, analysis, and regulatory approval.
An Estipham representative stated, "We will continue to expand our collaborations with global big pharma and biotech companies."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.